Patents Assigned to CB THERAPEUTICS INC.
  • Publication number: 20250011735
    Abstract: Provided is a nucleic acid comprising a recombinant bacterial or archaeal geranyl pyrophosphate synthase (GPPS) gene, codon optimized for production in yeast. Also provided is a yeast cell comprising an expression cassette comprising the above nucleic acid. Additionally provided is a method of producing a terpene or cannabinoid in a yeast, the method comprising incubating the above yeast cell in a manner sufficient to produce the terpene or cannabinoid.
    Type: Application
    Filed: January 26, 2022
    Publication date: January 9, 2025
    Applicant: CB Therapeutics, Inc.
    Inventors: Erin Marie Scott, Kirsten Tang, Jacob Michael Vogan
  • Patent number: 11987602
    Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: May 21, 2024
    Assignee: CB Therapeutics, Inc.
    Inventors: Erin Marie Scott, Jacob Michael Vogan
  • Publication number: 20230383314
    Abstract: Provided is an engineered olivetolic acid cyclase (OAC) enzyme derived from a microorganism or non-Cannabis plant, wherein the enzyme catalyzes cyclization of a polyketide (I) into a resorcyclic acid derivative (II), where R1=CH3, CH2CH3, (CH2)2CH3, (CH2)3CH3, (CH2)4CH3, (CH2)5CH3, or (CH2)6CH3 Also provided is nucleic acids encoding the above OAC enzyme, expression cassettes comprising those nucleic acids, and recombinant microorganisms comprising those expression cassettes that express the OAC enzyme encoded therein. Additionally provided is a method of converting a polyketide (I) into a resorcyclic acid derivative (II) comprising contacting the polyketide with the above-identified OAC enzyme in a manner and for a time sufficient to convert the polyketide (I) into the resorcyclic acid derivative (II).
    Type: Application
    Filed: May 27, 2022
    Publication date: November 30, 2023
    Applicant: CB Therapeutics, Inc.
    Inventors: Erin Marie Scott, Jacob Michael Vogan, Tyler Huelsman
  • Publication number: 20230313154
    Abstract: Provided is a nucleic acid comprising a sequence encoding a prenyltransferase (PT) gene or its complement, codon optimized for production in a microorganism or a plant. Also provided is a yeast expression cassette comprising the above nucleic acid. Additionally provided is a non-naturally occurring prenyltransferase (PT) comprising an amino acid sequence having at least 90% amino acid sequence identity or conservative amino acid substitutions to the amino acid sequences encoded by the above nucleic acid. Further provided is a recombinant microorganism or plant expressing a PT encoded by the above nucleic acid. Additionally provided is a method of catalyzing the condensation of a polyprenol diphosphate and an alkylresorcinol or alkylresorcyclic acid to yield a cannabinoid.
    Type: Application
    Filed: July 16, 2021
    Publication date: October 5, 2023
    Applicant: CB THERAPEUTICS, INC.
    Inventors: Erin Marie Scott, Jacob Michael Vogan, Tyrone Jacob Yacoub
  • Publication number: 20230242919
    Abstract: Provided are non-naturally occurring nucleic acids comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism. Also provided are a recombinant microorganisms expressing the enzyme or regulatory protein. Methods of expressing the enzyme or regulatory protein are additionally provided.
    Type: Application
    Filed: June 4, 2021
    Publication date: August 3, 2023
    Applicant: CB Therapeutics, Inc.
    Inventors: Laura Flatauer Peiffer, Jacob Michael Vogan, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
  • Publication number: 20220389467
    Abstract: The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.
    Type: Application
    Filed: August 1, 2022
    Publication date: December 8, 2022
    Applicant: CB Therapeutics, INC.
    Inventors: Jacob Michael Vogan, Laura Flatauer Peiffer, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
  • Publication number: 20220298533
    Abstract: Provided is a method of modifying a first cannabinoid into a second cannabinoid or a non-cannabinoid. The method comprises combining the first cannabinoid with an enzyme that can modify the first cannabinoid into the second cannabinoid or non-cannabinoid under conditions where the first cannabinoid is modified into the second cannabinoid or non-cannabinoid. Also provided is a non-naturally occurring enzyme that can modify a first cannabinoid into a second cannabinoid or a non-cannabinoid. A nucleic acid encoding that enzyme is additionally provided. Further provided is a non-naturally occurring nucleic acid that encodes an enzyme having the enzymatic activity of the above non-naturally occurring enzyme. An expression cassette comprising that nucleic acid is additionally provided. A cell comprising the above expression cassette is further provided. Also provided is a plant expression cassette comprising the above-identified nucleic acid.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 22, 2022
    Applicant: CB Therapeutics, Inc.
    Inventors: Erin Marie Scott, Jacob Michael Vogan
  • Patent number: 11441164
    Abstract: The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: September 13, 2022
    Assignee: CB THERAPEUTICS, INC.
    Inventors: Jacob Michael Vogan, Laura Flatauer Peiffer, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
  • Publication number: 20210388035
    Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 16, 2021
    Applicant: CB Therapeutics, Inc.
    Inventors: Erin Marie Scott, Jacob Michael Vogan
  • Patent number: 11041002
    Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: June 22, 2021
    Assignee: CB THERAPEUTICS, INC.
    Inventors: Erin Marie Scott, Jacob Michael Vogan
  • Patent number: 11028417
    Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular, modified, or synthetic gene(s) of select enzymes that are processed and inserted into an expression system (for example, a vector, cosmid, BAC, YAC, phage) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: June 8, 2021
    Assignee: CB THERAPEUTICS, INC.
    Inventors: Sher Ali Butt, Jacob Michael Vogan
  • Publication number: 20210147888
    Abstract: The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 20, 2021
    Applicant: CB Therapeutics, INC.
    Inventors: Jacob Michael Vogan, Laura Flatauer Peiffer, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
  • Patent number: 10988785
    Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular, modified, or synthetic gene(s) of select enzymes that are processed and inserted into an expression system (for example, a vector, cosmid, BAC, YAC, phage) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: April 27, 2021
    Assignee: CB THERAPEUTICS, INC.
    Inventors: Sher Ali Butt, Jacob Michael Vogan
  • Patent number: 10982243
    Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular, modified, or synthetic gene(s) of select enzymes that are processed and inserted into an expression system (for example, a vector, cosmid, BAC, YAC, phage) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: April 20, 2021
    Assignee: CB THERAPEUTICS, INC.
    Inventors: Sher Ali Butt, Jacob Michael Vogan
  • Patent number: 10671632
    Abstract: The methods and system disclose an automated pipeline which receives a list of Accession IDs corresponding to transcriptomic, proteomic, genomic, or metabolomic data. Each Accession ID is submitted in parallel, launching a specific cloud computer to carry out a customized, fully automated transcriptome assembly (or proteomic assembly or genome assembly or metabolome assembly) and analysis by the automated pipeline. The output from multiple assemblies is automatically compiled and compared with genes of interest to identify new gene variants. The new gene variants can be used as queries by the automated pipeline to: discover variants of the variants; and determine new studies to analyze.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: June 2, 2020
    Assignee: CB THERAPEUTICS, INC.
    Inventor: Tyrone Jacob Yacoub
  • Publication number: 20200063170
    Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the Cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.
    Type: Application
    Filed: August 28, 2019
    Publication date: February 27, 2020
    Applicant: CB Therapeutics, INC.
    Inventors: SHER ALI BUTT, JACOB MICHAEL VOGAN
  • Publication number: 20200063171
    Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.
    Type: Application
    Filed: August 28, 2019
    Publication date: February 27, 2020
    Applicant: CB Therapeutics, INC.
    Inventors: SHER ALI BUTT, JACOB MICHAEL VOGAN
  • Publication number: 20200031935
    Abstract: The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.
    Type: Application
    Filed: August 12, 2019
    Publication date: January 30, 2020
    Applicant: CB Therapeutics, Inc.
    Inventors: Jiping ZHA, Ziyong SUN, Junzhuan QIU
  • Patent number: 10435470
    Abstract: The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: October 8, 2019
    Assignee: CB Therapeutics, Inc.
    Inventors: Jiping Zha, Ziyong Sun, Junzhuan Qiu
  • Patent number: 10428146
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof that bind to PD-1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-1 antibodies and methods of use thereof.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: October 1, 2019
    Assignee: CB Therapeutics, Inc.
    Inventors: Junzhuan Qiu, Ziyong Sun, Jiping Zha